Christopher Mutz sold $227k of ANIP
HEAD OF RARE DISEASE at ANI PHARMACEUTICALS INC. 3,162 shares at an average of $71.64, traded Mar 13, 2026, filed Mar 13, 2026.
Score components
- +15RoleOfficer
- +13Trade size$227k at market
- 0Share of holdings soldSold 3.3% of holdings
- +15Cluster7 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001846487-26-000014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 13, 2026 | SOpen-market sale Common Stock10b5-1 | -3,162 | $71.64 | $227k | 91,309 | Mar 13, 2026 |
Related signals
Other insiders at ANI PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | ANI PHARMACEUTICALS INC | Stephen P. Carey SVP & CFO | $208k 2,850 shares | -2% | |
| 36Weak | ANI PHARMACEUTICALS INC | Nikhil Lalwani PRESIDENT & CEO | $383k 5,400 shares | -2% | |
| 18Weak | ANI PHARMACEUTICALS INC | Jeanne Thoma director | $72k 1,000 shares | -4% | |
| 16Weak | ANI PHARMACEUTICALS INC | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | $35k 500 shares | -1% | |
| 29Weak | ANI PHARMACEUTICALS INC | Stephen P. Carey SVP & CFO | $207k 2,850 shares | -2% | |
| 50Moderate | ANI PHARMACEUTICALS INC | Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | $357k 4,772 shares | -11% | |
| 16Weak | ANI PHARMACEUTICALS INC | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | $36k 500 shares | -1% | |
| 26Weak | ANI PHARMACEUTICALS INC | Christopher Mutz HEAD OF RARE DISEASE | $425k 5,723 shares | -6% | |
| 33Weak | ANI PHARMACEUTICALS INC | Krista Davis SVP, CHIEF HR OFFICER | $488k 6,572 shares | -11% | |
| 41Moderate | ANI PHARMACEUTICALS INC | Stephen P. Carey SVP & CFO | $552k 7,312 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.